November 12, 2021

Announcements

Greatest of Care

We are proud to announce that a new spot, part of Yale New Haven Health’s “Greatest of Care” campaign, has launched regionally to provide a spotlight on Smilow Cancer Hospital and our team approach to cancer care by nationally recognized leaders.

The advertisement will air frequently on all Connecticut broadcast TV stations (WFSB-3, WTNH-8, WVIT-NBC and FOX) as well as cable networks in Connecticut, Westchester County, and Southern Rhode Island. It will also air on popular streaming services. To complement the TV ad, radio spots, outdoor and print advertisements, and digital/social ads are also planned.

Watch Now

Chênevert Family Brain Tumor Center Leadership Named

We are pleased to announce the leadership team for The Chênevert Family Brain Tumor Center at Smilow Cancer Hospital and Yale Cancer Center. The Center was established earlier this year with a generous gift from Louis and Debra Chênevert and the Chênevert Family Foundation to create a leading center in brain tumor research and bring groundbreaking solutions and hope to patients with brain tumors.

To support and execute the Center’s mission, an Executive Cabinet has been established.

News Center

Yale Cancer Center Study Shows Rates of PSA Testing for Prostate Cancer Increased After Revised National Guidelines

Read More
To support and execute the Center's mission, an Executive Cabinet has been named for The Chênevert Family Brain Tumor Center to include Clinical Director Jennifer Moliterno, MD, FAANS; Clinical Trials Director Antonio Omuro, MD; and Scientific Director Ranjit Bindra, MD, PhD. Together, they will leverage the interdisciplinary nature of the Center to create a strategic approach to clinical and research growth and success.

Dr. Moliterno is an Associate Professor of Neurosurgery and Chief of Neurosurgical Oncology for Primary Brain Tumors. She joined Yale in 2013 and has specialized expertise in performing surgeries for complex tumors located in areas of the highly functioning brain. In her new role, Dr. Moliterno will work with all clinical members of The Chênevert Family Brain Tumor Center to create a signature of care for our patients with brain tumors throughout the Smilow Cancer Hospital Network, which features exceptional clinical quality and outcomes, easy, coordinated patient access, and an emphasis on a multidisciplinary team-based integrative care model.

As Clinical Trials Director, Dr. Omuro will oversee clinical research, ensuring a commitment to innovative, novel treatment options for our patients diagnosed with brain tumors. A Professor of Neurology and Chief of Neuro-Oncology, Dr. Omuro joined Yale Cancer Center and Smilow Cancer Hospital in 2018 from the University of Miami and is the lead principal investigator on several clinical trials at Yale Cancer Center. Along with Dr. Bindra, he is also the national co-principal investigator on the Glioblastoma Therapeutics Network and the associated grant through the U19, "Center of Innovation for Brain Tumor Therapeutics."

In his new role as Scientific Director, Dr. Bindra will partner closely with Dr. Omuro and Dr. Moliterno and work to facilitate the development of our brain tumor research community largely grounded in basic science, hypothesis-driven discovery across Yale Cancer Center and Smilow Cancer Hospital, and translational research that moves promising ideas from the lab to the clinic.
Yale Cancer Center and Smilow Cancer Hospital, and in collaboration with scientists throughout Yale University. Dr. Bindra is a Professor of Therapeutic Radiology and Chief of the Pediatric Central Nervous System Radiotherapy Program, and the recipient of numerous national grants to support his laboratory research program in DNA repair.

**Community Research Fellowship Program**

As part of a new program introduced by the Center for Community Engagement and Health Equity (CEHE), and in partnership with the Community Alliance for Research and Engagement (CARE), nine community members from New Haven joined five research groups at Yale Cancer Center for a 9-month Fellowship in 2021. The program provided training and support to hosting research groups on academic-community collaborations and delivered ongoing workshops for Fellows to introduce them to cancer and cancer research, health disparities, the social determinants of health, community-level health interventions, cancer prevention, and community-based participatory research. Hosting research groups were: The Joshi Lab (Mentors: Nikhil Joshi, PhD, Kelli Connolly, PhD); The Tobacco Center on Regulatory Sciences (Mentors: Suchitra Krishnan-Sarin, PhD, Grace Kong, PhD); The Townsend Lab (Mentor: Christopher Cross, PhD); Yale Smart Medicine Lab (YSML) (Mentor: Jun Deng, PhD); and the Smilow Cancer Genetics and Prevention Program (Mentors: Xavier Llor, MD, PhD, Tracy Sturrock, APRN). CEHE will soon be recruiting a new cohort of Fellows and YCC research group hosts to begin in 2022. Please contact Erin Singleton for more information.

**Notables**

Yale Cancer Center has renewed its American Cancer Society Institutional Research Grant. The grant is led by Daniel DiMaio, MD, PhD, Deputy Director of Yale Cancer Center, and has been continually funded for more than 40 years. The award provides $120,000 per year for three years for ‘seed money’ for the initiation of cancer-related projects by promising junior faculty investigators. The ACS IRG has had a profound impact launching the careers of YCC’s junior faculty, including academic promotion, the receipt of prestigious awards, and high impact publications.

Lieping Chen, MD, PhD, United Technologies Corporation Professor in Cancer Research and Professor of Immunobiology of Dermatology and of Medicine (Medical Oncology) and Co-Leader of Yale Cancer Center’s Cancer Immunology Research Program, has been named an inaugural Fellow of the Academy of Immuno-Oncology by the Society for Immunotherapy of Cancer.

$13 Million Grant to Study Malignant Brain Tumors Awarded to YSPH Researcher and Colleagues
Nicole Deziel, PhD, MHS, Associate Professor of Epidemiology (Environmental Health) and a member of Yale Cancer Center’s Cancer Prevention and Control Research Program, has been awarded an American Cancer Society Research Scholar Grant to fund her project, “Thyroid Hormone Disrupting Chemicals and Pediatric Thyroid Cancer.” Dr. Deziel’s proposal seeks to understand if early-life exposure to environmental thyroid hormone-disrupting chemicals may be associated with childhood thyroid cancer. Other YCC members involved with the project include Xiaomei Ma, Joshua Warren, Krystal Pollitt, Catherine Dinauer.

Murat Gunel, MD, Chair and Nixdorff-German Professor of Neurosurgery, Professor of Genetics and Neuroscience, and a member of Yale Cancer Center’s Genomics, Genetics, and Epigenetics Research Program, received the WINN Award at the meeting of the Society of Neurological Surgeons last month in Austin, Texas. This prestigious award is given each year to a distinguished neurosurgeon-scientist who has demonstrated an outstanding, continuous commitment to academic neurosurgery with unparalleled contributions to the field and science.

Roy S. Herbst, MD, PhD, Chief of Medical Oncology, participated in the Eli 2021 Conference on Wednesday, November 3 and presented along with Robin Stern, Associate Director for the Yale Center for Emotional Intelligence, on “Emotional Intelligence is the Rx.” Dr. Herbst also presented advances in lung cancer during a joint session between ASCO and Russian Society of Clinical Oncology (RUSSCO) on November 9.

Dwain Fehon, PsyD, Associate Professor of Psychiatry, recently chaired and moderated an international panel presentation for the International Psycho-oncology Society titled, “COVID’s Global Impact on Palliative Care: Creating Connections.” The panel consisted of eight palliative care experts and included a roundtable discussion that examined some of the key challenges and opportunities for palliative care patients, families, and providers in developed and developing countries around the world. Representing the U.S. was Jennifer Kapo, MD, Sherwin B. Nuland & Michael K. Vlock Associate Professor of Palliative Medicine and Director of Palliative Medicine, Yale Cancer Center.

The Genetics, Genomics, and Epigenetics Research Program welcomes Michael Murray, MD, FACMG, FACP, Professor of Genetics and Pathology and Director for Clinical Operations in the Center for Genomic Health. Dr. Murray bridges genomic science with clinical care delivery. He has decades of experience in conducting large population-wide genome sequencing studies and currently leads the Clinical Operations in the Center for Genomic Health at Yale. Dr. Murray is also Principal investigator of the GENERATIONS germline sequencing project that will create an unprecedented data resource for Program members and the broader scientific community.
Xiao Xu, PhD, MA, has joined the Cancer Prevention and Control Research Program. Dr. Xu is an Associate Professor of Obstetrics, Gynecology & Reproductive Sciences and a faculty member of the Yale Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center and Yale Center for Outcomes Research and Evaluation (CORE). Trained in health economics and outcomes research, Dr. Xu has extensive experience in health services research seeking to promote the delivery of high-quality and high-value care. Her research focuses on examining and identifying factors that influence the quality, outcomes, and value of care, with a focus on women's health care. Dr. Xu's current R01-funded research is examining barriers to early diagnosis of uterine cancer in Black women which directly aligns with the CPC emphasis of social determinants of health (SDOH).

Diversity, Equity, and Inclusion

BMSF-AACR Design and Implementation of Clinical Trials Workshop
On Saturday, November 6th, Roy S. Herbst, MD, PhD, kicked off the BMSF-AACR Design and Implementation of Clinical Trials Workshop. Dr. Herbst commented, "Together we will make a difference for the health of our diverse communities. This workshop is just one step in focusing on and tackling health disparities on a larger scale." The six-day workshop focused on principles of good clinical trial design and research practice by presenting the ongoing challenges in clinical research; highlighting the benefits of focusing on clinical research, specifically in underrepresented populations; and investigating the disconnect between communities and clinical trials by utilizing highly innovative approaches to clinical research. After the workshop, each participant was provided with a mentor based on their research specialty with whom they will work for two years.

Employee Profile: Kerstyn Deskin

When COVID-19 started to impact Connecticut in March 2020, Kerstyn

Read More

November 10 was World NET Cancer Day, which was designated to raise awareness about neuroendocrine cancers and the need for timely detection and diagnosis. Neuroendocrine tumors are slow growing cancers that arise from neuroendocrine cells and are often found in the gastrointestinal tract. Also referred to as carcinoid cancer, neuroendocrine tumors are rare and affect about 12,000 patients each year.

Nearly 90% of new NET patients are incorrectly diagnosed and initially treated for the wrong disease because the symptoms are often confused with other gastrointestinal concerns. At Smilow Cancer Hospital, our specialists have unique experience caring for patients with NETs, both at the time of diagnosis and throughout the continuum of their treatment.

Read More

Donna Watkins, RN, is a practice nurse on

Read More
Deskin was two months into her new job as Clinical Operations Manager of the NP1 Gynecologic Oncology Clinic. Kerstyn had arrived from a private practice where she was manager for 19 years and was adjusting to all of the changes that come with joining a large institution from a small practice.

In clinical operations, Kerstyn’s responsibilities as manager include helping fulfill any needs requested by the Gyn-Onc providers, assisting with patients and patient issues, billing questions, clinic problems, equipment requests, and she helps cover other floors in the North Pavilion – mostly floors 4, 7, and 8.

However, once COVID started to take hold and space to care for COVID and oncology patients in Smilow became a premium, Kerstyn helped move her clinic three times in four months. As the only manager on-site while others were helping in North Haven, Kerstyn had to manage staffing, IT, implementation of visitation changes and social distancing, as well as constant staff changes, all while learning her job on the fly.

“Thinking about my first six months with Smilow, I look back and all I can say is ‘wow,’” says Kerstyn. “It was trial by fire, but everyone from leadership to managers were so amazing and helpful. It was a chaotic time and while I was new, we were all in it together, and we became family.”

Overall, Kerstyn loves the clinic environment and how her role is very hands-on. From the beginning of her career, she has always worked in oncology, explaining that she loves watching patients at the start of their cancer journey to their ‘graduation.’

Maureen Major Campos, RN, MS, Director of Smilow Ambulatory Services, says, “Kerstyn is a ‘can-do’ employee. She brings warmth and professional communication to all she encounters and is a true patient advocate. She leads by example, and we are fortunate to have her on our team.”

---

**OOTB Thanks Laurene Goode!**

Yale Cancer Center and Smilow Cancer Hospital’s #OUTOFTHEBLUETHANKS recently recognized Laurene Goode, a Senior Administrative Assistant II at Yale Cancer Center. During the recent fellowship interview season, Laurene proactively offered her assistance to the fellowship team during their virtual interview days. In the hematology floor at Smilow Cancer Hospital, NP7. For nearly the last two years she has balanced her workdays with patient and administrative support. She coordinates patient prescriptions, schedules doctors, processes Family Medical Leave Act (FMLA) requests, and performs general patient support. Most of all, she especially enjoys working on an oncology floor.

Donna began her career at Yale New Haven Hospital as an Emergency Department Technician Assistant (EDTA) and she decided to go back to nursing school at age 50 and become an RN. After graduation, Donna started on NP11 before entering the Resource Pool to learn more about internal medicine. Inspired by a family member’s battle with cancer, she decided to return to oncology and accepted a position on NP7. Donna retained her chemotherapy certificate and continues to check on patients who are visiting for their infusion therapy and assists with access ports.

Donna loves the doctors, she loves the patients, and everything about her job on the good and bad days, but mostly, she simply cares about people. “A lot of people run from cancer and feel it’s taboo, but I think cancer is misunderstood. Patients are scared, but they are still human. With so much of their battle being psychological, they just need a conversation or a hug. You have to be kind because anyone can have cancer and you never know who is going through a personal battle.”
Virtual interview days. In preparation for the virtual interviews, Laurene helped teach the team how to use the Zoom breakout rooms, which were an essential part of the process. Having the extra support from Laurene on the interview days to help monitor the Zoom sessions and move participants around as needed truly helped the team make sure the candidates were having a smooth experience. Laurene’s help was an excellent example of teamwork, and we are so grateful she is part of our team. Thank you, Laurene!

Yale Cancer Center & Smilow Cancer Hospital’s #OUTOFTHETHANKS program is a staff recognition initiative to show appreciation to employees who have exemplified an above-and-beyond effort or an outstanding contribution to the team. If you are interested in submitting a nomination, please complete this nomination form and return it to the Director’s Office c/o Anna Raso.

NCCN Resources

One of the benefits of institutional membership in NCCN is that all staff employed at NCCN Member Institutions receive free access to the Library of NCCN Compendia. Recommendations contained in NCCN Compendia are extracted directly from the relevant NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and help support clinical decision-making related to the use of drugs and biologics, biomarker testing, radiation therapy, and imaging for patients with cancer. The Compendia are organized by disease type and reviewed by members of the relevant NCCN Guidelines Panel before publication.

The Library of NCCN Compendia includes:
1. NCCN Drugs & Biologics Compendium (NCCN Compendium®)
2. NCCN Biomarkers Compendium®
3. NCCN Radiation Therapy Compendium®
4. NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™)

Recent Publications

Read More

Buza, N. Immunohistochemistry in Gynecologic Carcinomas: Practical Update with Diagnostic and Clinical Considerations Based on The 2020 WHO Classification Of Tumors. Seminars in Diagnostic Pathology, Online ahead of print.
Read More


Renee Moye, APRN, one of the outstanding members of our Smilow Cancer Hospital Care Center team in Fairfield, was awarded the Tai-Jaih Davis “Caretaker” Award by the Sister Girl Foundation in recognition of her service to our patients and her community with compassion, tenacity, and dedication during the COVID-19 pandemic. The Award is sponsored by the American Cancer Society Making Strides Against Breast Cancer Walk and was presented to Renee on October 17 at the annual walk at Sherwood Island. Congratulations, Renee!

Stand Up To Cancer (SU2C) has announced the Stand Up To Cancer–Fanconi Anemia Research Fund–Farrah Fawcett Foundation Head and Neck Cancer Research Team. Co-led by Barbara Burtness, MD, Professor of Medicine (Medical Oncology), Interim Associate Cancer Center Director for Diversity, Equity and Inclusion, and Co-Leader, Developmental Therapeutics Program, the team will concentrate on new approaches to address head and neck cancer.

Targeting Prostate Cancer with Clostridium Perfringens Enterotoxin Functionalized Nanoparticles Co-encapsulating Imaging Cargo Enhances Magnetic Resonance Imaging Specificity

Read More


Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC

Read More

Tan C, Mandell JD, Dasari K, Cannataro VL, Alfaro-Murillo JA, Townsend JP.

Heavy Mutagenesis by Tobacco Leads to Lung Adenocarcinoma Tumors with KRAS G12 Mutations Other Than G12D, Leading KRAS G12D Tumors-On Average-To Exhibit A Lower Mutation Burden

Read More

Lu J, Zhao M, Arai Y, Zhong BY, Zhu HD, Qi XL, de Baere T, Pua U, Yoon HK, Madoff DC, Teng GJ.

Clinical practice of transarterial chemoembolization for hepatocellular carcinoma: consensus statement from an international expert panel of International Society of Multidisciplinary Interventional Oncology (ISMIO).


Read More


Read More


Physachenolide C Induces Complete Regression of Established Murine Melanoma Tumors via Apoptosis And Cell Cycle Arrest

Translational Oncology, Online ahead of print.

Read More

On November 17 at 4:30pm, join a virtual book reading with the authors behind the stories in the anthology, Spirituality Through Our Struggle. Listen as they share how their spirituality and outlook on life has helped them deal with their illness. The authors have different illnesses, different ways of coping, and different beliefs, but every author offers a message that will encourage you and inspire you whether you are a patient, caregiver, or clinician.
Factors Affecting Time to Surgery in Breast Cancer Patients
The American Surgeon, Online ahead of print.
Read More

Clark M, Tchrakian N, Clarke B, Metser U, Bouchard-Fortier G.
Placenta Increta Mimicking Placental Site Trophoblastic Tumor
Read More

Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic Leukemia in the United States
Blood Advances, Online ahead of print.
Read More

A Plain Language Summary of Results from The ADAURA Study: Osimertinib after Surgery for Patients who Have Early-stage EGFR-Mutated Non-Small Cell Lung Cancer
Future Oncology, Online ahead of print.
Read More

Comparison of Metabolic and Immunologic Responses to Transarterial Chemoembolization with Different Chemoembolic Regimens in a Rabbit VX2 Liver Tumor Model
European Radiology, Online ahead of print.
Read More

Kaushik Tiwari M, Colon-Rios DA, Tumu HCR, Liu Y, Quijano E, Krysztofiat A, Chan C, Song E, Braddock DT, Suh HW, Saltzman WM, Rogers FA.
Direct Targeting of Amplified Gene Loci for Proapoptotic Anticancer Therapy
Nature Biotechnology, Online ahead of print.
Read More

Nezami N, VAN Breugel JMM, Konstantinidis M, Chapiro J, Savic LJ, Miszczuk MA, Rexha I, Lin M, Hong K, Georgiades C.
Lipiodol Deposition and Washout in Primary and Metastatic Liver Tumors After Chemoembolization
In Vivo, 35(6):3261-3270.
Read More

Mattes MD, Suneja G, Haffty BG, Takita C, Katz MS, Ohri N, Deville C Jr, Siker ML, Park HS.
Overcoming Barriers to Radiation Oncology Access in Low-Resource Settings in the United States
Advances in Radiation Oncology, 6(6):100802.
Read More
Advances in Radiation Oncology, 6(6):100802.

Holt EH.
Current Evaluation of Thyroid Nodules

Read More

Wang M, Hui P.
A Timely Update of Immunohistochemistry and Molecular Classification in the Diagnosis and Risk Assessment of Endometrial Carcinomas
Archives of Pathology & Laboratory Medicine, 145(11):1367-1378.

Read More

Wang M, Gilani S, Xu H, Cai G.
Salivary Gland-type Tumors of the Lung
Archives of Pathology & Laboratory Medicine, 145(11):1379-1386.

Read More

Bui MM, Zhang LLJ, Wang HP.
Updates and Diagnostic Challenges in Surgical Pathology and Cytopathology
Archives of Pathology & Laboratory Medicine, 145(11):1355-1357.

Read More

Dietary Supplement Use and Interactions with Tamoxifen and Aromatase Inhibitors in Breast Cancer Survivors Enrolled in Lifestyle Interventions.
Nutrients 2021, 13, 3730.

Read More

Enasidenib Plus Azacitidine Versus Azacitidine Alone in Patients with Newly Diagnosed, Mutant-IDH2 Acute Myeloid Leukaemia (AG221-AML-005): A Single-Arm, Phase 1b and Randomised, Phase 2 Trial

Read More

Jairam V, Pasha S, Soulos PR, Gross CP, Yu JB, Park HS, Decker RH.
Post-operative Radiation Therapy for Non-Small Cell Lung Cancer: a Comparison of Radiation Therapy Techniques

Read More

Chundydyal S, Cheng JY, Wang M, Li FY, Colegio OR.
Skin Cancer Incidence in Organ Transplant Recipients Referred for Benign Skin Conditions

Read More

During #breastcancerawarenessmonth, Yale Radiation Oncologist Dr. Christin Knowlton says, “The number one way oncology providers can support patients is by providing an atmosphere that encourages questions and to discuss challenges they face.”

The Yale Surgery Citizen Awards Committee has named Ronald Salem, MD, FACS, MBChB, Lampman Professor of Surgery (Surgical Oncology) the 2022 recipient of The Dr. Walter E. Longo MD Award. Established in 2019, the award recognizes one faculty member per year who has made a significant positive influence on the cultural legacy of the Department of Surgery. Congratulations, Dr. Salem!
Financial Toxicity in Patients with Gynecologic Malignancies: A Cross Sectional Study

Read More

Funding and Award Opportunities

Limited Competition: Coordinating Center for the Small Cell Lung Cancer Consortium (U24)
The purpose of this limited competition FOA is to continue support for the Coordinating Center (CC) for the Small Cell Lung Cancer (SCLC) Consortium that will be focused on prevention, diagnosis, treatment, and mechanisms of treatment resistance in SCLC.
**Application Deadline:** November 17, 2021

Read More

Understanding Oral HPV Infection, Acquisition, and Persistence in People Living with HIV (R01, R21)
The purpose of these FOAs are to solicit research to better understand the epidemiology and biology of oral HPV infection, its acquisition and persistence, in people living with HIV and elucidate the initial mechanisms related to HPV-associated oral and oropharyngeal cancers and warts in the context of HIV.
**Application Deadline:** November 18, 2021

Read More

A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials (U01)
Through this FOA, the NCI solicits applications for CUSP2CT, a program that will implement and evaluate multilevel and culturally tailored outreach and education interventions with the primary goal of increasing referral and ultimately, accrual of underrepresented racial/ethnic (R/E) minority populations, to NCI-supported clinical trials, NCI's Community Oncology Research Program, and Experimental Therapeutics Clinical Trials Network.
**Application Deadline:** November 19, 2021

Read More

Data, Evaluation and Coordinating Center for: A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials (U24)
The purpose of this FOA is to solicit applications for Connecting Underrepresented Populations to Clinical Trials U24 Data, Evaluation and Coordinating Center.
**Application Deadline:** November 19, 2021

Read More

Lion Heart Fund for Cancer Research
Supports breast cancer research - providing pilot funding to kick-start high potential research projects, and/or supporting innovative work requiring bridge funding. Contact Janine.hoffman@yale.edu for funding announcement and guidelines.
**Internal Deadline:** November 22, 2021

Read More
ASCI's 2022 Young Physician-Scientist Awards
With these awards, the ASCI seeks to recognize early-career physician-scientists who have made notable achievements in their research, and to encourage and inspire them through their participation in the Joint Meeting and related programming.

Application Deadline: November 22, 2021
Read More

Launching soon: ASCI Emerging-Generation Awards
These awards recognize post-MD, pre-career physician-scientists who are meaningfully engaged in immersive research, giving them access to the Joint Meeting and longitudinal programming similar to the YPSA program. Entry into the ASCI network at this stage is intended to provide peer support and inspiration to stay the course into a physician-scientist faculty appointment. Look for E-Gen Awards nominations to open in late October. Contact programs@the-asci.org for more information.

AACR Clinical Oncology Research (CORE) Training Fellowships
Designed for early-career clinical scientists who hold a medical degree (MD, DO, or MD/PhD) and are interested in acquiring the knowledge and skills related to clinical trial design and execution from the perspective of the pharmaceutical industry. The fellow will gain real-world experience in drug development, including clinical research, clinical trial design, and data analysis.

Application Deadline: November 30, 2021
Read More

AACR Career Development Award to Further Diversity, Equity, and Inclusion in Clinical Cancer Research
This award has been established to support the development and diversity of highly talented cancer researchers from underrepresented groups (as per NIH guidelines) in the field of clinical cancer research.

Application Deadline: November 30, 2021
Read More

Breast Cancer Research Foundation-AACR Career Development Awards to Promote Diversity and Inclusion
These awards represent a focused effort to encourage and support investigators from diverse backgrounds traditionally excluded in cancer research and to foster their career advancement. This grants program also intends to build a more diverse and inclusive future for breast cancer research.

Application Deadline: November 30, 2021
Read More

DeLuca Center for Innovation in Hematology Research
Five pilot awards will be awarded to support investigators pursuing research in Hematology and to generate preliminary data for new NCI/NIH grant applications. The research should seek to advance our knowledge in Hematologic disorders and to improve patient care, therapies, and outcomes.

Letter of Intent Due: December 1, 2021 to richard.carr@yale.edu
Read More

The NCCN Foundation 2022 Young Investigator Award (YIA) Program
The NCCN Foundation, the NCCN Foundation invites proposals from the premier cancer centers in the United States. "—@DrEricWiner talks to @YaleDailyNews on his appointment as @YaleCancer Director.

This Thursday #VeteransDay, from 8am-12pm @SmilowCancer Trumbull is offering free lungcancer screening for current and former smokers at Park Avenue Medical Center. Veterans in attendance will receive a Challenge Coin. Visit http://bit.ly/3C2kr5C for more info.

Congrats to Jun Deng, PhD! Dr. Deng will be inducted as a 2021 Fellow of the American Society for Radiation Oncology FASTRO at a ceremony in recog. of his contributions to the #RadOnc field at ASTRO21 at 10:45am.

"This is a real opportunity to both have a big impact on cancer care in CT & beyond CT, & to really enhance the research that's already being done there."—@DrEricWiner talks to @TheCancerLetter on his appt. as @YaleCancer Dir.

@NCIDirector Dr. Ned Sharpless – "It’s hard to overstate the importance of the #NationalCancerAct. It united patients, doctors, scientists, industry, and government in a common vision."

Congratulations to @ranjitbindra ! Dr. Bindra and his team were recently awarded funding from @GatewayforCR to support biomarker studies in a phase I/II clinical trial testing PARP inhibitors in IDH1/2-mutant glioma.

Congratulations to @SiggyN5 Sigrid Nachtergaele, PhD, awarded a $600K competitive 2021 @sontagfdn Early Career Scientist Award to research braincancer!

Congratulations to Kaelyn Sumigray, PhD @ksumigray, recipient of an @ACS_Research Scholar Award to support her research to identify novel therapeutic targets to prevent polyp formation and transformation.
Through its YIA Program, the NCCN Foundation invites proposals from young investigators with innovative ideas and an interest in improving the quality, effectiveness, efficiency and accessibility of care provided to patients with cancer.

**Deadline for Nomination:** December 1, 2021

Read More

Howard Hughes Medical Institute: Hanna H. Gray Fellows Program 2022
HHMI seeks to increase diversity in the biomedical research community. The goal of the Hanna H. Gray Fellows Program is to recruit and retain individuals from gender, racial, ethnic, and other groups underrepresented in the life sciences, including those individuals from disadvantaged backgrounds.

**Application Deadline:** December 1, 2021

Read More

The Hope Foundation for Cancer Research SEED Fund for SWOG Early Exploration and Development 2021
These awards may assist investigators with projects that support the following types of studies: pre-clinical data, secondary data analysis from clinical trials, pilot and feasibility studies (including early stage clinical trials), small, self-contained research projects, or development of research methodology/technology. $50,000

**Application Deadline:** December 1, 2021

Read More

DKMS Stiftung Leben Spenden (Foundation for Giving Life) - John Hansen Research Grant
This grant is intended to provide financial support to as many as four talented international young scientific researchers who want to advance the fight against blood cancer with their promising research projects in the field of blood stem cell transplantation and cell therapy.

**Application Deadline:** December 3, 2021

Read More

HEAL Initiative: Advancing Health Equity in Pain Management (R61/R33 Clinical Trial Required)
The purpose of this FOA is to solicit applications to accelerate development, testing and implementation of evidence-based interventions— that are culturally and linguistically appropriate for NIH-designated populations that experience health disparities in the United States—to mitigate disparities in provision of care and treatment decisions, reduce susceptibility to chronic pain and improve patient outcomes.

**Application Deadline:** December 9, 2021

Read More

The Conquer Cancer – Breast Cancer Research Foundation Research Professorship for Diversity and Inclusion in Breast Cancer
Provides flexible funding to outstanding researchers who have made, and are continuing to make, significant contributions in breast cancer research and will dedicate their time in training future breast cancer researchers.

**Letter of Intent Due:** December 14, 2021

Read More

The Conquer Cancer – Breast Cancer Research Foundation Advanced Clinical Research Award (ACRA) for Diversity and Inclusion in Breast Cancer Research

Read More
Cancer Research
Designed with the primary goal of increasing diversity in the oncology workforce and cancer research. Awards will be given to mid-career investigators who are members of racial and/or ethnic groups traditionally excluded in academic medicine and biomedical research, and who wish to conduct original breast cancer research not currently funded.

**Letter of Intent Due:** December 14, 2021

Read More

HEAL Initiative: Pragmatic and Implementation Studies for the Management of Sickle Cell Disease Pain (UG3/UH3)
The purpose of this FOA is to solicit cooperative agreement applications to conduct multisite embedded pragmatic or implementation trials to inform the uptake of pharmacologic, nonpharmacologic, and/or multicomponent approaches for acute and/or chronic sickle cell disease (SCD) pain management in health care systems that serve the SCD population. Trials may include or allow continuation of opioid medication as needed; however opioid medication use alone should not be the only intervention studied. Trials supported under this initiative could also address social and structural barriers such as stigma and racial bias to SCD pain management care.

**Application Deadline:** December 15, 2021

Read More

The purpose of this FOA is to solicit cooperative agreement applications to support multisite effectiveness clinical trials of pharmacologic, nonpharmacologic, and/or multicomponent approaches for acute and/or chronic sickle cell disease (SCD) pain management, allowing continued opioid pain management as needed.

**Application Deadline:** December 15, 2021

Read More

Implementation Science for Cancer Control in People Living with HIV in Low- and Middle-Income Countries (U01)
The purpose of this FOA is to support and accelerate the integration of evidence-based cancer control interventions for PLWH by leveraging existing HIV treatment and prevention infrastructure.

**Application Deadline:** December 15, 2021

Read More

Alex’s Lemonade Stand Foundation (ALSF) and RUNX1 Early Career Investigator Grant
The purpose of this grant is to promote the establishment of a new generation of translational and clinical researchers interested in tackling inherited hematologic malignancy predisposition disorders with a focus on RUNX1-familial platelet disorder.

**Application Deadline:** December 20, 2021

Read More

Coordinating Center for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (U24)
Through this FOA, the NCI solicits applications from institutions/organizations to participate in the Clinical Sites for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network. The 'CASCADE' network will conduct clinical trials to test the efficacy and safety of interventions aimed at reducing the incidence of HIV and cervical cancer in populations at high risk for these diseases.
'CASCADE' Clinical Trials Network. The 'CASCADE' Network will conduct pragmatic clinical trials evaluating the effectiveness of clinically proven interventions to overcome barriers and reduce failures in the cervical cancer screening, management, and precancer treatment cascade for women living with HIV.

**Application Deadline:** December 28, 2021

Read More

**Research Bases for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (UG1)**

As an integral part of this Cooperative Agreement-funded network, this FOA will (i) provide scientific and statistical leadership for developing network clinical trials concepts and protocols, overseeing their conduct, and analyzing and publishing their results, (ii) ensure compliance with human research participant protection and other regulatory and administrative reporting requirements, and (iii) work towards creating opportunities for training emerging investigators.

**Application Deadline:** December 28, 2021

Read More

**Clinical Sites for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (UG1)**

As an integral part of this Cooperative Agreement-funded network, this FOA will provide a pluripotent infrastructure for accruing participants to network clinical trials, interface with the UG1 Research Bases and U24 Network Coordinating Center during concept and protocol development to provide insights and input on clinical significance and study feasibility and provide on-site operational leadership for the successful conduct of the network clinical trials.

**Application Deadline:** December 28, 2021

Read More

**Yale Cancer Center K12 Calabresi Immuno-Oncology Training Program Scholar Awards**

We are pleased to solicit applications for the Yale Cancer Center (YCC) K12 Calabresi Immuno-Oncology Training Program (IOTP) Scholar Award for junior faculty to enhance research skills beyond the training provided during graduate and postgraduate training.

**Application Deadline:** January 3, 2022

Read More

**YCC Cancer Microbiome Pilot Grants**

Thanks to the generosity of a private donor, YCC seeks to fund early-stage laboratory investigations that will advance our understanding of the host microbiome and microbial niches in cancer progression and therapy. Cancer associated microorganisms include bacteria, viruses, fungi, and parasites.

**Application Deadline:** January 3, 2021

Read More

**Mary Kay Ash Foundation Cancer Research Grant**

This grant focuses on funding research for innovative grants for translational research of cancers affecting women (ovarian, uterine, breast, endometrial or cervical cancer among others).

**Internal Deadline:** January 3, 2021

Read More
Brain Research Foundation: Brain Research Foundation Seed Grant Program 2022
The objective of the BRF Seed Grant Program is to support new and innovative projects, especially those of junior faculty, who are working in new research directions. BRF Seed Grant awards are not intended to supplement existing grants.
**Application Deadline:** January 4, 2021
Read More

AACR Cancer Disparities Research Fellowships
These represent an effort to encourage and support postdoctoral or clinical research fellows to conduct cancer disparities research and to establish a successful career path in this field. The research proposed for funding may be basic, translational, clinical, or epidemiological in nature and must have direct applicability and relevance to cancer disparities.
**Application Deadline:** January 7, 2022
Read More

CDA for Inclusion and Diversity in Breast Cancer Research
Designed with the primary goal of increasing diversity in the oncology workforce and cancer research. This CDA will provide funding to clinical investigators who have received their initial faculty appointment and identify as members of racial and/or ethnic groups traditionally excluded in academic medicine and biomedical research.
**Application Deadline:** January 10, 2022
Read More

YIA for Diversity and Inclusion in Breast Cancer Research
Provides funding to promising investigators to encourage and promote quality research in clinical oncology. The purpose of this grant is to fund physicians during the transition from a fellowship program to a faculty appointment.
**Application Deadline:** January 10, 2022
Read More

HESI THRIVE
THRIVE, a partner in the 2018 Biden Cancer Initiative, provides seed grants for nonclinical, clinical, and translational research and technology-based solutions that enhance our ability to predict when and how adverse effects may occur in patients who have received cancer treatment. THRIVE also supports the development of approaches to avoid or lessen these effects.
**Letter of Intent Due:** January 10, 2022
Read More

BMSF Diversity in Clinical Trials Career Development Program
The intent of this program is to increase diversity in clinical trials. The initiative is comprised of a Career Development Program for early-stage clinical investigators and a Clinical Investigator Pipeline Program (BMSF CIPP) for rising second-year medical students.
**Application Deadline:** January 14, 2022
Read More

Please submit your recent publications, awards, and grant announcements to:

**Renee Gaudette**
Director, Public Affairs and Communications